FY2026 EPS Estimates for MariMed Raised by Noble Financial

Posted by on May 19th, 2026

MariMed Inc. (OTCMKTS:MRMD – Free Report) – Noble Financial increased their FY2026 EPS estimates for shares of MariMed in a note issued to investors on Friday, May 15th. Noble Financial analyst J. Gomes now expects that the company will earn ($0.04) per share for the year, up from their prior estimate of ($0.05). The consensus estimate for MariMed’s current full-year earnings is ($0.05) per share. Noble Financial also issued estimates for MariMed’s Q4 2026 earnings at ($0.03) EPS.

MariMed Stock Up 7.4%

Shares of MRMD stock opened at $0.07 on Tuesday. The company has a debt-to-equity ratio of 1.67, a quick ratio of 0.34 and a current ratio of 0.95. The firm’s 50-day moving average is $0.08 and its 200-day moving average is $0.09. The stock has a market cap of $28.54 million, a price-to-earnings ratio of -2.38 and a beta of 1.33. MariMed has a 52-week low of $0.06 and a 52-week high of $0.23.

MariMed (OTCMKTS:MRMD – Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.01). The company had revenue of $39.48 million for the quarter, compared to analysts’ expectations of $38.75 million. MariMed had a negative net margin of 7.82% and a negative return on equity of 5.00%.

About MariMed

(Get Free Report)

MariMed Inc is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.

Further Reading

Receive News & Ratings for MariMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MariMed and related companies with MarketBeat.com's FREE daily email newsletter.